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Abstract: Clear cell papillary renal cell carcinoma (ccpRCC) and
renal angiomyoadenomatous tumor (RAT) share morphologic
similarities with clear cell (ccRCC) and papillary RCC (pRCC).
It is a matter of controversy whether their morphologic, im-
munophenotypic, and molecular features allow the deﬁnition of
a separate renal carcinoma entity. The aim of our project was to
investigate speciﬁc renal immunohistochemical biomarkers in-
volved in the hypoxia-inducible factor pathway and mutations
in the VHL gene to clarify the relationship between ccpRCC and
RAT. We investigated 28 ccpRCC and 9 RAT samples by im-
munohistochemistry using 25 markers. VHL gene mutations
and allele losses were investigated by Sanger sequencing and
ﬂuorescence in situ hybridization. Clinical follow-up data were
obtained for a subset of the patients. No tumor recurrence
or tumor-related death was observed in any of the patients.
Immunohistochemistry and molecular analyses led to the re-
classiﬁcation of 3 tumors as ccRCC and TFE3 translocation
carcinomas. The immunohistochemical proﬁle of ccpRCC and
RAT samples was very similar but not identical, diﬀering from
both ccRCC and pRCC. Especially, the paraﬁbromin and
hKIM-1 expression exhibited diﬀerences in ccpRCC/RAT
compared with ccRCC and pRCC. Genetic analysis revealed
VHL mutations in 2/27 (7%) and 1/7 (14%) ccpRCC and RAT
samples, respectively. Fluorescence in situ hybridization analysis
disclosed a 3p loss in 2/20 (10%) ccpRCC samples. ccpRCC and
RAT have a speciﬁc morphologic and immunohistochemical
proﬁle, but they share similarities with the more aggressive renal
tumors. On the basis of our results, we regard ccpRCC/RAT as
a distinct entity of RCCs.
Key Words: kidney, clear cell papillary renal cell cancer, cyto-
keratin 7, VHL, renal angiomyoadenomatous tumor, clear cell
renal cell carcinoma
(Am J Surg Pathol 2015;39:889–901)
C lear cell papillary renal cell carcinoma (ccpRCC) hasbeen proposed as a new entity of renal cell cancer by
the International Society of Urological Pathology to be
included in the next World Health Organization Classi-
ﬁcation of Renal Tumors.1 It was initially discovered in
kidneys with end-stage renal disease in 2006.2 Since then
>100 ccpRCC cases have been described, and the majority
were found in normal functioning kidneys.3–8 They are
characterized by tumor cells with clear cytoplasm, linear
arrangement of low-grade nuclei located apically distant
from the basal membrane, and containing varying amounts
of tubular, papillary, and cystic architecture. Strikingly, the
ccpRCCs lack mitoses, atypia, pleomorphism, necrosis,
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hyaline globules, foamy macrophages, and vascular in-
vasion. Despite signiﬁcant morphologic, immunohisto-
chemical, and genetic similarities to clear cell RCC
(ccRCC) and papillary RCC (pRCC), characteristic genetic
diﬀerences include VHL gene mutations and 3p losses,
found in ccRCC. Gain of the chromosomes 7 and 17 or loss
of chromosome Y are absent or extremely rare in ccpRCC
cases.4,9,10 No disease-deﬁning mutation has been identiﬁed
to date.
The renal angiomyoadenomatous tumor (RAT) was
ﬁrst reported in the kidney of a 93-year-old man by
Michal et al.11 Nine years later, the same group charac-
terized 5 additional tumors.12 Verine13 pointed out that
ccpRCCs are a major diﬀerential diagnosis of RAT and
emphasized their morphologic, immunohistochemical,
molecular, and clinical similarities. In the literature many
terms have been used to probably describe the same entity,
including ccRCC with prominent leiomyomatous pro-
liferation and RCC with smooth muscle stroma.12,14–17
The epithelial component of ccpRCC and RAT is
composed of cells with abundant clear cytoplasm, strong
diﬀuse CK7 activity, and low-grade nuclei (Fuhrman
grades 1 and 2). Because of their many similarities, several
authors regard ccpRCC and RAT to be a variant of the
same entity.6,9,13,17,18
The aims of our study were to clarify the relation-
ship between ccpRCC and RAT and to identify markers
to reliably distinguish ccpRCC and RAT from the bio-
logically more aggressive renal neoplasms.
MATERIALS AND METHODS
Case Cohort
All tumors were consultation cases fromH.M. and E.C.
and were received from Austria, France, Germany, Italy, and
Switzerland. Hematoxylin and eosin–stained slides were re-
viewed for morphologic features of ccpRCC and RAT as
previously described.3,5–7,11,12,19 Diagnostic features of
ccpRCC include tumor cells with abundant clear cytoplasm,
varying papillary, cystic, and tubular architecture, low-grade
nuclei (Fuhrman grades 1 and 2) located apically distant from
the basal membrane, and strong diffuse CK7 and CA-IX
expression. For diagnosis of RAT, the following criteria were
required: cells with clear cytoplasm, low-grade nuclei
(Fuhrman grades 1 and 2) embedded in a smooth muscle
stroma, and strong diffuse CK7 staining of the epithelial
component. Tumors were staged according to the TNM sys-
tem20 and graded according to Fuhrman et al.21 The mor-
phologic characteristics were scored as previously described.7
Immunohistochemistry
A total of 25 antibodies were selected as (i) they are
involved in theVHL signaling pathway, (ii) they are known to
be prognostic biomarkers of ccRCC, and (iii) they have been
reported as markers of ccpRCCs and RATs in a small group
of ccpRCCs described in recent USCAP meetings (2011 to
2014). Tissue microarray sections (2.5mm) were transferred to
glass slides and treated using Ventana Benchmark XT, Bond-
max (Leica Microsystems) automated systems, and manual
protocols. Tissue microarray construction was not possible
in 5 of the ccpRCC cases because of the absence of tissue.
The immunohistochemical staining product was described
as nuclear, membranous, or cytoplasmic (Table 1). The im-
munohistochemistry results were interpreted as 0 (negative),
1+ (weak staining), 2+ (moderate staining), and 3+ (strong
staining). For statistical analysis, all 2+ and 3+ stainings
were deﬁned as positive and 0 and 1+ as negative. Antibodies
and protocols are listed in Table 1.
Fluorescence In Situ Hybridization
Fluorescence in situ hybridization (FISH), performed to
detect VHL allele losses, was carried out using the ZytoLight
SPEC VHL/CEN 3 Dual-color Probe (ZytoVision,
Bremerhaven, Germany). Tissue sections were cut from for-
malin-ﬁxed paraﬃn-embedded (FFPE) blocks, deparaﬃnized,
and hybridized as previously described.22 Sixty non-
overlapping tumor nuclei from 3 diﬀerent areas were ana-
lyzed, and the number of VHL and CEN3 signals was
recorded for each nucleus. The total number of VHL and
CEN3 signals as well as the VHL/CEN3 ratio and the per-
centage of tumor cells with <2 VHL signals were calculated.
Tumors were considered VHL deleted if >50% of the tumor
nuclei displayed <2 VHL signals.23 In 2 cases TFE3 FISH
using SPEC TFE3 dual-color break-apart probe from Zyto-
Vision was performed on whole sections as previously de-
scribed by our group.24
VHL Sequencing Analysis
Tumor areas displaying >80% tissue in the epi-
thelial portion of the ccpRCC and RAT were marked on
the hematoxylin and eosin slides. DNA from FFPE tu-
mor tissue samples was obtained by punching 1 to 2 tissue
cylinders (diameter 0.6mm) from each sample. DNA was
extracted from the tumor tissue samples according to the
Maxwell 16 FFPE Plus DNA Puriﬁcation protocol
(Promega, Fitchburg) for automated DNA puriﬁcation.
DNA concentrations in the samples were measured using
the Nanodrop (Thermo Fisher Scientiﬁc, Waltham, MA).
Polymerase chain reaction (PCR) of the VHL gene was
performed as previously described25 using approximately
40 ng of DNA for each ampliﬁcation. DNA sequencing
was performed with the dideoxy chain-termination
method using the BigDye Terminator v1.1 Cycle Se-
quencing kit (Applied Biosystems, Foster City). The same
forward and reverse primers were used for PCR and se-
quencing analyses. Cycle sequencing products were ana-
lyzed using the AbiPrism 3100 Genetic analyzer (Applied
Biosystems). The obtained sequences were compared with
the NCBI sequence AF010238 using NCBIs Blast 2 Se-
quences. All VHL point mutations obtained were vali-
dated by a second separate PCR and sequencing analysis.
RESULTS
Clinical and Pathologic Findings
The patients with ccpRCC ranged from 29 to 75
years of age (mean age 58 y) and those with RAT from 32
to 68 years of age (mean age 43.3 y) at the time of
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nephrectomy. The male to female ratio was 1.5:1 in the
ccpRCC group (17 men and 11 women) and 3.5:1 in the
RAT group (6 men and 1 woman).
Clinical follow-up data were available for 78% (21/
27) of the ccpRCC patients and 71% (5/7) of the RAT
patients. Mean follow-up time was 29.7 months (range, 7
to 84mo) for the ccpRCC patients and 32.3 months
(range, 25 to 38mo) for the RAT patients. There was no
evidence of recurrence or disease-related death in any of
the patients. None of the RAT (0/5) patients and 14% (3/
22) of the ccpRCC patients had end-stage renal disease.
In the RAT group, the average diameter of the tumor
was 3.1 cm (range, 1.8 to 5.0 cm) compared with 2.6 cm
(range, 0.5 to 8 cm) in the ccpRCC group. Among the RAT
patients, 67% (4/6) displayed pathologic stage pT1a and
33% (2/6) stage pT1b. Overall, 86% of the tumors (6/7)
were Fuhrman nuclear grade 1, and 14% (1/7) were nuclear
grade 2. In the ccpRCC cases, 77% (20/26) were stage
pT1a, 19% (5/26) were pT1b, and 4% (1/26) were pT2a.
Fuhrman nuclear grade 1 was found in 48% (13/27) and
nuclear grade 2 in 52% (14/27) of the tumors. All the
ccpRCCs and 6/7 RATs showed at least focal papillary
architecture and branched ducts. In contrast to ccpRCC,
secretory cells were completely absent in the RAT cases.
Both showed variable amounts of cystic areas. All tumors
were characterized by the absence of mitotic formations,
foamy macrophages, calciﬁcations, and vascular invasion.
Table 2 summarizes the clinicopathologic ﬁndings.
Morphologic characteristics are shown in Table 3.
Immunohistochemical Findings
The immunohistochemical ﬁndings are detailed
in Table 4. ccpRCC and RAT were strongly positive
for CK7, CK19, CA-IX, GLUT-1, E-cadherin, vimentin,
b-catenin, paraﬁbromin, PAX-2, PAX-8, p27, p53, and c-
MET. Staining for GLUT-1 (P=0.0572), CD70 (P=
0.1499), and p16 (P=0.3702) diﬀered slightly in the RAT
samples compared with ccpRCCs, although diﬀerences did
not show statistical signiﬁcance. Following the recent results
by Cui et al,26 Aron et al,27 and Schwartz et al,28 we tested
paraﬁbromin, hKIM-1,29 and CD133 expression to distinguish
ccpRCC/RAT from ccRCC/pRCC. As shown in Table 5, the
expression diﬀerence reached statistical signiﬁcance (P<
0.0001). The biomarkers CD70,30 MET,31 and E-cadherin32
were able to distinguish between ccpRCC/RAT and ccRCC
(P<0.0001). Furthermore, the hKIM-1 and paraﬁbromin
were able to distinguish between ccpRCC/RAT and pRCC.
All ccpRCC cases exhibited a characteristic CA-IX “cup-like”
distribution, sparing the luminal border as it has been de-
scribed in the literature before.6,33 In contrast, the RAT tu-
mors and the ccpRCC-like tumor with the VHL mutation
showed a circumferential membranous staining pattern. Two
RAT samples stained weakly positive for TFE3 and were,
therefore, further analyzed by HMB45 and TFEB. Both
stainings revealed a negative result. In addition, TFE3 FISH
was performed (see below).
FISH Findings
Three deletions of the short arm of chromosome 3
were identiﬁed. All of them occurred in the ccpRCC cases
(3/21, 14%), and no deletion was found in the RAT cases
(0/7, 0%). The presence of the 3p deletions in the 1
ccRCC controls was correctly identiﬁed. In 9 of the cases
FISH was not performed, as there was insuﬃcient tissue
after VHL mutation analysis and immunohistochemistry.
TFE3 FISH was performed with the 2 above-men-
tioned RAT-like cases that showed weak TFE3 ex-
pression. One case showed the typical break-apart pattern
TABLE 1. Antibody Overview
Antibody Clone Species Vendor Dilution Staining Pattern
b-catenin 14/Beta-Catenin Mouse BD Biosciences 1:50 Membranous
Carbonic anhydrase IX — Rabbit Abcam Limited 1:6000 Membranous (partially cytoplasmatic)
c-MET SP44 Rabbit Ventana Prediluted Membranous
CD10 SP67 Mouse Ventana Prediluted Membranous
CD70 301731 Mouse R&D Systems 1:75 Membranous
CD133 — Rabbit Abcam Limited 1:500 Membranous
Cytokeratin 7 OV-TL 12/30 Mouse Dako A/S 1:100 Membranous
Cytokeratin 19 RCK108 Mouse Abcam Limited 1:200 Membranous
E-cadherin EP700Y Rabbit Cell Marque Lifescreen Ltd 1:200 Membranous
Estrogen receptor SP1 Rabbit Labvision 1:50 Nuclear
GATA3 L50-823 Mouse Biocare Medical 1:250 Nuclear
GLUT-1 — Rabbit Millipore Corporation 1:1000 Membranous
hKIM-1 — — Bonventre lab — Membranous and cytoplasmatic
Melanosome HMB45 Mouse Dako A/S 1:50 Cytoplasmic
OCT3/4 N1NK Mouse Novocastra Laboratories Ltd 1:150 Nuclear
p16 JC8 Mouse Santa Cruz Biotechnology Inc. 1:200 Nuclear
p27 — Rabbit Santa Cruz Biotechnology Inc. 1:30 Nuclear
p53 DO-7 Mouse Dako A/S 1:80 Nuclear
Paraﬁbromin 2H1 Mouse Santa Cruz Biotechnology Inc. 1:10 Nuclear
PAX-2 — Rabbit Zymed Laboratories Inc. 1:100 Nuclear
PAX-8 — Rabbit Protein Tech Group Inc 1:200 Nuclear
Progesterone receptor 1E2 Rabbit Ventana Prediluted Nuclear
TFE3 MRQ-37 Rabbit Cell Marque Lifescreen Ltd. Prediluted Nuclear
TFEB — Goat Santa Cruz Biotechnology Inc. 1:100 Nuclear
Vimentin Vim 3B4 Mouse Dako A/S 1:250 Cytoplasmatic
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in >85% of the cells, whereas the second case was neg-
ative. Both cases were reclassiﬁed as translocation carci-
nomas because of immunohistochemical TFE3 positivity.
VHL Gene Mutation Analysis
Three VHL mutations were detected in the ccpRCC
group (3/27, 11%) in exon 2 (c.351G>C/p.Trp117Cys,
c.461C>T/p.Pro154Leu, c.388G>C/p.Val130Leu) and 1
in the RAT group (1/7, 14%) in exon 1 (c.174_177delGCCG/
p.Pro59GlyfsX7). We identiﬁed 2 cases, harboring both a
VHLmutation and 3p loss. One case showed a 3p loss but no
VHLmutation, and 2 cases with aVHLmutation showed no
3p loss (Figs. 1–5).
DISCUSSION
In the present study we have sequenced the largest
number of ccpRCC29 and RAT7 cases to date. We found
a VHL mutation rate of 11% in ccpRCC and 14% in
RAT. Furthermore, we analyzed hypoxia-inducible factor
pathway–related proteins to compare these findings with
recent findings.
ccpRCC and RAT are currently underrecognized.
Recent studies have revealed that they are not rare7,34,35 and
that among all RCCs the ccpRCCs have a prevalence rate
between 1.2% and 4.1%, thus representing up to 4500 new
cases of renal cancer in the United States annually.7,34,36
Awareness of its morphologic and immunohistochemical
features is imperative for a correct classiﬁcation. In a recent
publication Gill et al35 underscored the necessity of re-
classifying low-grade and low-stage ccRCC, as up to 7% of
the cases are in fact ccpRCC.
Morphologically, ccpRCC and RAT share many
features. Their epithelial component is composed of cells
with clear cytoplasm and low-grade nuclei. Both tumors
have various amounts of smooth muscle stroma, and their
epithelial component is characterized by either cystic or
papillary architecture. In our cohort the majority of the
RAT samples had focal papillary features of the epithelial
TABLE 2. Clinicopathologic Findings
# Age Sex Laterality
Grade
(Fuhrman)
Size
(cm)
No.
Tumors Stage ESRD
Tumor-
related
Death
Follow-
up (mo)
Tumor
Recurrence Metastasis Special Remarks
RAT
1 32 M Right 2 1.8 1 pT1a No NA NA No No
2 32 M Left 2 4.7 2 pT1b NA NA NA NA NA
3 34 M Right 2 1.8 2 pT1a NA No 35 NA NA IBD, pRCC type 1,
kidney adenomas
4 45 F Right 2 NA 1 NA NA NA NA NA NA
5 56 M Left 2 2 1 pT1a No No 25 No No
6 68 M NA 1 3.5 1 pT1a NA NA NA NA NA
7 36 M Left 2 5 1 pT1b No No 19 No No
CCPRCC
1 55 M NA 2 NA NA NA NA NA NA NA NA
2 58 M Right 2 0.9 1 pT1a No NO 39 No No
3 57 F Right 1 4 1 pT1b NA NO 25 NA NA
4 50 M NA 2 3 1 pT1a NA NA NA NA NA
5 38 M Left 2 2 1 pT1a Yes NA NA NA NA IgA nephritis
6 63 M Right 2 2 NA pT1a NA NA NA NA NA Large cell b-cell
lymphoma
7 62 M Left 2 3 2 pT1a No No 12 No No pRCC type 2
8 31 F Left 2 8 1 pT2a NA NA NA NA NA
9 55 M Right 1 4.5 1 pT1b No No 24 No No
10 68 F NA 1 3.8 pT1a NA Na NA NA NA
11 51 M Left 2 1.3 1 pT1a No No 11 No No
12 75 F Left 2 5.1 1 pT1b No No 7 No No
13 38 M Left 1 2.2 1 pT1a No No 8 No No
14 53 F Right 1 2 1 pT1a No No 84 No No
15 51 M Left 2 1 8 pT1a No No 71 No No
16 62 M Left 1 1.3 1 pT1a Yes No 67 No No
17 52 M Left 1 5 1 pT1b No No 60 No No
18 71 F Right 2 2.5 1 pT1a No No 39 No No
19 57 F Left 1 1.5 1 pT1a No No 37 No No
20 72 M NA 1 0.5 2 pT1a No No 29 No No
21 61 F Left 2 5 1 pT1b No No 22 No No
22 71 M Right 1 2 1 pT1a No No 21 No No
23 53 F Right 1 1 3 pT1a No No 17 No No
24 70 F Left 1 2.8 1 pT1a No No 15 No No
25 65 F NA 1 0.5 1 pT1a No No 14 No No
26 74 M Left 2 1.8 1 pT1a Yes No 12 No No
27 54 M Left 2 2 1 pT1a No No 10 No No
ESRD indicates end-stage renal disease; IBD, inﬂammatory bowel disease; NA, not available.
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component, which are typically diﬀuse CK7 and CA-IX
positive. The most relevant diﬀerential diagnoses include
ccRCC that exhibit papillary features, pRCC exhibiting
clear cell characteristics, and Xp11 translocation carci-
noma. In our cohort, 2 cases initially classiﬁed as RAT
had to be reclassiﬁed as Xp11 translocation carcinomas
after immunohistochemical and TFE3 FISH analyses.
The translocation carcinomas were identiﬁed by nuclear
TFE3 protein expression. Only 1 case showed a positive
TFE3 FISH result. It is controversial whether TFE3
positivity is suﬃcient to diagnose TFE3 translocation
carcinoma,24,37 but, from these 2 cases, we concluded that
TFE3 translocation cancer falls within the diﬀerential
diagnostic spectrum of ccpRCC/RAT. Another diﬀer-
ential diagnosis for the case with weak TFE3 staining and
negative FISH is TFEB-associated RCC. Those tumors
can overlap tremendously with the TFE3-rearranged
RCC.38,39 To rule out this diﬀerential diagnosis, we per-
formed 2 additional immunohistochemical stainings
(HMB45 and TFEB). Both stainings showed a negative
result making that diﬀerential diagnosis unlikely.
One ccpRCC case was reclassiﬁed as ccRCC. That
case exhibited typical ccpRCC morphology but was
completely negative for CK7 and strongly positive for
hKIM-1. This case also revealed a mutation in the VHL
gene and a 3p loss in the FISH analysis. These ﬁndings
highlight the importance of molecular testing and should
raise awareness of ccpRCC mimicking ccRCC.40
VHL gene mutations are the genetic hallmark of
ccRCC. Initially, it was reported that VHL alterations are
absent in ccpRCC. However, 3 groups have recently
identiﬁed VHL mutations in ccpRCC at frequencies
varying from 15% to 27%.41–43 In concordance with these
studies, we also identiﬁed VHL gene alterations in
ccpRCC, but the prevalence of VHL gene mutations is
signiﬁcantly lower than in ccRCC.44–46 The discrepancy
between the number of mutations found in our ccpRCC
cases and that reported may be explained by the diﬀerent
detection methods used, including single-nucleotide
polymorphism genotyping array and Sanger sequencing,
and by the limited number of cases in previous studies.
Alternatively, cases with VHL mutations could represent
ccRCCs with morphology and immunoproﬁle closely
mimicking that of clear ccpRCC and RAT tumor. Cur-
rently, ccpRCCs are diagnosed on the basis of morphol-
ogy and diﬀuse strong CK7 expression. The absence of
VHL mutations/3p deletions is not diagnostic for
ccpRCC. Therefore, we suggest diagnosis of tumors with
diﬀuse CK7 expression combined with the typical mor-
phology as ccpRCC. In previous studies, ccRCCs with a
diﬀuse CK7 proﬁle have had a completely diﬀerent
prognosis than ccRCCs without that CK expression
pattern.47 These previous ﬁndings justify such an ap-
proach.VHL inactivation leads to an HIF-dependent CA-
IX and GLUT-1 upregulation. We only found few VHL
TABLE 3. Morphologic Characteristics of RAT and ccpRCC
#
Papillary
Architecture
Branched
Ducts
Secretory
Cells
%
Cystic
RAT
1 1f Yes No 15
2 0 No No 0
3 2f Yes No 65
4 1f Yes No 5
5 2f Yes No 0
6 1f Yes No 55
7 2f Yes No 15
ccpRCC
1 1 Yes Yes 85
2 2 Yes No 10
3 3 Yes Yes 10
4 3 Yes No 10
5 2 Yes No 15
6 3 Yes Yes 55
7 1 Yes Yes 0
8 3 Yes No 0
9 3 Yes No 0
10 2 Yes No 5
11 3 Yes No 0
12 3 Yes Yes 40
13 1 Yes Yes 15
14 1 Yes No 5
15 2 Yes No 20
16 2 Yes No 10
17 1 Yes Yes 15
18 3 Yes Yes 45
19 2 Yes No 30
20 2 Yes Yes 20
21 2 Yes No 5
22 1 Yes No 10
23 3 Yes Yes 55
24 1 Yes Yes 10
25 3 Yes No 35
26 2 Yes Yes 5
27 3 Yes Yes 30
Scored as previously described.7
F indicates focal.
TABLE 4. Results of Immunohistochemistry
Antibody ccpRCC RAT
b-catenin 95.5 85.7
CA-IX 95.5 85.7
CD10 31.8 66.7
CD70 22.7 0
CD133 81.8 100
c-MET 91.3 100
CK7 100 100
CK19 88.9 100
E-cadherin 100 100
Estrogen receptor 4.3 0
GATA3 31.8 42.9
GLUT-1 95.5 85.7
hKIM-1 23.8 0
OCT3/4 8.7 0
p16 18.2 42.9
p27 100 100
p53 72.7 71.4
Paraﬁbromin 95.5 100
PAX-2 63.6 100
PAX-8 95.5 100
Progesterone receptor 0 0
Vimentin 95.5 100
Percentage relates to number of interpretable cases.
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mutations but in combination with CA-IX and GLUT-1
immunoreactivity in both ccpRCC and RAT. This clearly
sets the ccpRCC and RAT apart from ccRCC, which
shows VHL mutations in up to 80% of the cases.44,48
Therefore, we believe that the HIF pathway may be ac-
tivated in a VHL-independent manner in most ccpRCCs
and RATs, also hypothesized by Rohan et al.6
Recently, Lawrie et al49 found various mutations in
ccpRCC by using next-generation sequencing, including a
nonsynonymous T992I mutation in the MET proto-on-
cogene. This gene was originally described as causing
hereditary pRCC.50 Interestingly, Lawrie and colleagues
detected no VHL mutation, but found overexpression in
all 5 members of the miR-200 family. The miR-200 family
plays an essential role in tumor suppression by inhibiting
epithelial-mesenchymal transition.51 To support Lawrie
and colleagues’ results, we also noted immunoreactivity
for E-cadherin and b-catenin. These ﬁndings suggest that
epithelial-to-mesenchymal transition may be incomplete
or blocked in ccpRCC contributing to their indolent
course.49
Other genetic alterations characteristic for pRCC
include gain of chromosome 7 and loss of chromosome Y.
However, in ccpRCC, gain of chromosome 7 has very
rarely been reported,4,5,9,10 and no loss of chromosome Y
has been observed to date. Fisher et al52 found a unique
gene expression proﬁle of ccpRCC when investigating 8
diﬀerent genes, with only some expression levels com-
parable to those observed in ccRCC and pRCC.
In our FISH analysis, we identiﬁed 3 chromosome
3p deletions in 20 ccpRCC and 7 RAT samples. All 3p
deletions occurred in ccpRCC with a frequency of 14.3%,
but none was detected in RAT. To date, only 4 cases with
a 3p loss have been reported in ccpRCC.36,43 Interestingly,
the single case described by Martignoni et al43 con-
currently harbored a VHL mutation like 2 of our 3 cases
with a 3p loss. Shi et al36 also used FISH and observed
monosomy of chromosome 3 in 3 cases in a series of 11
ccpRCCs all lacking mutations in the VHL gene. In 2009,
Shannon et al14 published a study on 5 ccRCCs with
smooth muscle stroma and found loss of the entire chro-
mosome 3 in 2 cases and a 3p loss in 1 case using FISH. In
contrast, Martignoni et al17 found no 3p loss in a series of
3 cases of ccRCC with smooth muscle stroma. Given these
molecular ﬁndings, it has been suggested that RAT and
ccRCC with smooth muscle stroma are interchangeable
terms.53 However, some of the cases of ccRCC with
smooth muscle stroma, particularly those that showed 3p
loss, might represent ccRCCs with exuberant, inﬁltrative
smooth muscle, whereas the others might in fact be RAT
tumors, particularly the ones that do not show 3p loss.15
In addition, recent data show that some tumors with RAT
morphology and immunophenotype share a common
mutation in the TCEB1 gene, which inactivated the
VHL pathway and upregulated proteins along the hypoxia-
inducible pathway.54 Twenty-ﬁve diﬀerent antibodies
were used to characterize ccpRCC and RAT. We were
particularly interested in hypoxia-inducible factor path-
way–related proteins and other antibodies, which were
reportedly used in small series of ccpRCC cases in the 2011
and 2014 USCAP meetings. This gave us the opportunity
to compare immunohistochemical findings in ccpRCC and
RAT to clarify their interrelationship. Remarkably, there
were no statistically significant differences in the staining
properties in any of the antibodies in ccpRCC compared
with RAT.
Paraﬁbromin and hKIM-1 expression levels diﬀered
signiﬁcantly between ccpRCC/RAT and ccRCC/pRCC.
Cui et al26 recently demonstrated that paraﬁbromin can
be very helpful in diﬀerentiating ccpRCC from ccRCC
and pRCC. In a study by Aron et al,27 the diﬀerence in
the staining positivity rate of ccpRCC and ccRCC was
even more striking compared with our study. In addition
to paraﬁbromin and hKIM-1 expression, CD70 also
proved to be a useful marker in diﬀerentiating ccpRCC
from ccRCC, as CD70 expression is rare in ccpRCC and
very frequent in ccRCC. CD70 was used for immuno-
histochemistry, because we have previously demonstrated
that CD70 is a potential biomarker for ccRCC.30,55 The
importance of immunohistochemical stainings in the
correct identiﬁcation of true ccpRCC was also highlighted
by Williamson et al.56 They studied 14 ccpRCC-like
tumors, which could not be distinguished from ccpRCC
morphologically, but which showed a high 3p deletion
frequency (82%) and showed a diﬀerent immunohisto-
chemical proﬁle, with negative or localized CK7 staining
as the most striking feature. These characteristics also led
to a reclassiﬁcation of 1 of our tumors, primarily diag-
nosed as ccpRCC.
Recently, Schwartz et al studied diﬀerent stem cell
markers in renal cancers. They reported a 90% positivity
rate for OCT3/4 in a series of 10 ccpRCC samples.28 This
TABLE 5. Different Expression Patterns of hKIM-1, Parafibromin, CD70, CD133, MET, and E-cadherin in ccPRCC, ccRCC, and
pRCC (Own Data and Literature)
Antibody ccpRCC (n [%]) ccRCC (n [%]) Fisher Exact (P) pRCC (n [%]) Fisher Exact (P)
hKIM-1 6/22 (27.3) 54/73 (74)29 <0.0001 28/30 (93)29 <0.0001
Paraﬁbromin 21/23 (91.3) 4/61 (7)26 <0.0001 7/37 (19)26 <0.0001
CD70 6/23 (26.1) 197/252 (78)30 <0.0001 113/348 (32)30 0.6475
CD133 18/23 (78.3) 3/21 (14.3)31 <0.0001 8/15 (53)31 0.16
MET 21/23 (91.3) 0/96 (0)32 <0.0001 18/20 (90)32 1
E-cadherin 22/22 (100) 22/69 (31.9)33 <0.0001 NA NA
NA indicates not available.
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ﬁnding is discrepant to our positivity rate of 8.7%, which
may be due to the use of diﬀerent antibodies or im-
munohistochemical protocols. However, similarly to
Schwartz et al,28 we also detected a high positivity rate of
stem cell marker CD133 (81.8% and 100%, respectively)
in ccpRCC. Interestingly, Schwartz and colleagues
FIGURE 1. ccpRCC. Hematoxylin and eosin stain (A) and typical immunohistochemical profile with diffuse membranous CK7
positivity (B), membranous “cup-like” CA-IX positivity (C), nuclear parafibromin positivity (D), hKIM-1 negativity (E), and CD133
positivity (F).
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reported a CD133 positivity rate of only 14% in ccRCC.
It can therefore be concluded that CD133 is an additional
tool to distinguish ccRCC from ccpRCC/RAT.
In concordance with Munari et al,57 we found that
about one third of ccpRCC are positive for GATA3, a
protein crucial for the regulation of Th2 development and
FIGURE 2. Hematoxylin and eosin morphology of a ccpRCC-like (A–C) and a RAT-like (D–F) case. Diagnostic features of ccpRCC
include tumor cells with abundant clear cytoplasm, varying papillary, cystic and tubular architecture, and low-grade nuclei
(Fuhrman grades 1 and 2) located apically distant from the basal membrane. The epithelial part of RAT tumors is composed of
cells with clear cytoplasm and low-grade nuclei (Fuhrman grades 1 and 2) embedded in a smooth muscle stroma.
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function. However, given that only a moderate staining
intensity was seen in no more than 10% of the tumor
cells, we do not consider OCT3/4 and GATA3 as diag-
nostic tools to diﬀerentiate ccpRCC from ccRCC.
No previous studies have reported cancer-related
death, vascular invasion, or metastasis in ccpRCC,4–7,53,58
suggesting that the disease follows an indolent course.
Benign biological behavior was also observed in all
WT:
Exon 2 Intron 1
WT:
Exon 1
A
D
E
B C
FIGURE 3. Molecular features of a ccpRCC-like (A) and a RAT-like (C) case both exhibiting a circumferential CA-IX staining
pattern, harboring a VHL mutation (D: c.174_177delGCCG/p.Pro59GlyfsX7; E: c.351G>C/p.Trp117Cys) and a 3p deletion
detected by FISH (B). The mutation sites are denoted by an arrow. The boundaries between exon and intron are indicated. The
upper base pair letter sequence shows the wild-type (WT) sequence (D and E). Tumor cells harbor only 1 VHL (green) signal and 2
CEN3 copies (orange) (B).
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RAT cases.12,14,59 This is comparable to multilocular
cystic RCC, which has an excellent prognosis with no
disease recurrence after surgery.7,12,59 Speciﬁc molecular
alterations may account for the indolent course of mul-
tilocular cystic RCC. Proposals have been put forward to
rename multilocular cystic RCC as multilocular cystic
c.461C>T/ p.Pro154Leu
Exon 2 Intron 2
A B
C
E
D
FIGURE 4. ccpRCC look-alike showing classic ccpRCC morphology on the hematoxylin and eosin stain (A), with, however, a
typical ccRCC immunohistochemical profile showing CK7 negativity (B), CA-IX positivity (C), hKIM-1 positivity (D), and proof of
VHL mutation (E).
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renal cell neoplasm of low malignant potential to under-
score this speciﬁc biological behavior.1 Our group has
reported that the expression of p27, CA-IX, CK7, and
CK19 is associated with a better prognosis in sporadic
RCC.47,60 Interestingly, our ccpRCC/RAT cases stained
strongly positive for all of these markers. Hence, the in-
dolent clinical course of ccpRCC/RAT might in part be
due to this speciﬁc signaling pathway. However, some of
the low-grade ccRCCs included in our previous pub-
lications may in fact be unrecognized ccpRCC.35,47
In summary, we have demonstrated that ccpRCC and
RAT cannot be distinguished from one another by im-
munohistochemistry and molecular analyses, and both
follow a benign clinical course. We regard them as a
spectrum of a distinct tumor entity. Precise diagnosis is
crucial, as it has an excellent prognosis. Given the reliability
of TFE3 immunohistochemistry, TFE3 FISH should be
performed in cases with equivocal TFE3 immunohisto-
chemistry.37 Taking into account the controversial
relevance of the VHL mutation analysis in this diﬀerential
diagnosis, direct VHL sequencing is not helpful in separa-
tion of ccRCC with prominent smooth muscle stroma from
RAT. Our results suggest that a panel of antibodies against
CK7, paraﬁbromin, and MET is a helpful tool to diﬀer-
entiate most ccpRCCs/RATs from other renal tumors
(Table 5). In some diﬃcult cases VHL mutation testing and
TFE3 FISH analysis are helpful tools to distinguish ccRCC
and TFE3 translocation carcinoma from ccpRCC/RAT.
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